In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

“Living alone, I rely on my parents and friends to help with daily tasks during flares,” she shares. “This experience has ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

CCAR-168 is under clinical development by AbelZeta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple ...

Zanubrutinib is under clinical development by BeiGene and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition success ...

A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...

Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares.

INR:9278. sky vegas best slots Analysis of Proton Pump Inhibitors Genentech announces latest results of CD20 antibody in treating lupus nephritis 5 new drug ...

INR:1720. sydney vezina R&D Daily丨CellCell® for lupus nephritis is launched in the country FDA delays decision date on Intercept's potential first NASH drug, obe ...